APA
Luo Y., Paul S. K., Zhou X., Chang C., Chen W., Guo X., Yang J., Ji L. & Wang H. (20170626). Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes. : Journal of diabetes research.
Chicago
Luo Yingying, Paul Sanjoy K, Zhou Xianghai, Chang Cuiqing, Chen Wei, Guo Xiaohui, Yang Jinkui, Ji Linong and Wang Hongyuan. 20170626. Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes. : Journal of diabetes research.
Harvard
Luo Y., Paul S. K., Zhou X., Chang C., Chen W., Guo X., Yang J., Ji L. and Wang H. (20170626). Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes. : Journal of diabetes research.
MLA
Luo Yingying, Paul Sanjoy K, Zhou Xianghai, Chang Cuiqing, Chen Wei, Guo Xiaohui, Yang Jinkui, Ji Linong and Wang Hongyuan. Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes. : Journal of diabetes research. 20170626.